ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update

Author(s): Danina M. Muntean, Lorand Kiss, Norbert Jost, Istvan Baczko

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 8 , 2015

Become EABM
Become Reviewer
Call for Editor


Ischemia and heart failure-related cardiac arrhythmias, both atrial (e.g., atrial fibrillation) and ventricular (e.g., malignant tachyarrhythmias) represent a leading cause of morbidity and mortality worldwide. Despite the progress made in the last decade in understanding their pathophysiological mechanisms there is still an unmet need for safer and more efficacious pharmacological treatment, especially when considering the drawbacks and complications of implantable devices. Cardiac ATP-sensitive potassium channels located in the sarcolemmal membrane (sarcKATP) and the inner mitochondrial membrane (mitoKATP) have emerged as crucial controllers of several key cellular functions. In the past three decades a tremendous amount of research led to their structural and functional characterization unveiling both a protective role in cardiac adaptive responses to metabolic stress and a seemingly paradoxical role in promoting as well as protecting against atrial and ventricular arrhythmias. On the other hand, several KATP inhibitors have emerged as potential ischemia selective antiarrhythmic drugs. In this respect, cardioselective, chamber specific and combined sarcKATP and mitoKATP modulators currently represent a promising field for drug development.

Keywords: Sarcolemmal and mitochondrial ATP-sensitive potassium channels, cardiac arrhythmias, pharmacological modulators.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1091 - 1102]
Pages: 12
DOI: 10.2174/1381612820666141029102800
Price: $65

Article Metrics

PDF: 30